Market research
CERO CERo Therapeutics Holdings, Inc. Common Stock
NASDAQ USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 716K
- P/E ratio
- 0.0
- Analyst target
- 30
- Dividend yield
- Not available
- Beta
- 0.21
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US71902K3032
- Market cap
- 716K
- P/E ratio
- 0.0
- Analyst target
- 30
- Dividend yield
- Not available
- Beta
- 0.21
About
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the CERO discussion.
No comments yet
Start a focused discussion about CERO.